reason report
r/r dlbcl come initi label focu indic expans
bottom line yesterday morn morphosi held
earn confer call provid updat quarter
financi pipelin tafasitamab us launch prepar
compani track launch tafasitamab r/r dlbcl us
come month approv like pdufa date
launch prepar near complet sale forc
recruit train two month ago manufactur
prepar progress well disrupt expect
suppli chain compani expect first batch commerci
suppli deliv upon approv morphosyss key pipelin
program materi impact covid view
cash hand multipl pipelin product enter commercial-stag
next year tafa us tafa eu mm
otilimab ra mophosi abl significantli
acceler expand tafasitamab develop indic
also expect compani engag busi develop
activ come year
manag suggest best case scenario includ
r/r dlbcl label dlbcl patient
evalu tafa l-mind studi potenti inclus treatment
label offer great competit advantag compar
late line treatment r/r diffus larg b-cell lymphoma dlbcl
label treatment dlbcl drug reach
annual run-rat three quarter post-launch even
approv believ tafa like outperform polivi given car-t
tafa forecast point slower launch due impact estimate
first two quarter sale vs polivi believ
better label and/or milder expect impact could
tafasitamab studi current on-going includ phase
first-mind studi dlbcl phase cosmo studi
cll phase confirmatori b-mind studi r/r dlbcl
compani plan initi addit studi tafasitamab
indic follicular lymphoma combin differ b-
cell deplet agent inhibitor late-stag asset
also make progress despit disrupt morphosyss
partner i-mab china recent dose first patient
compani inform svb leerink llc research
revenu mm
dcf analysi discount rate
net debt total capit
year price history/av daili volume mil mor gy
pleas refer page import disclosur price chart analyst certif
phase studi multipl myeloma anticip gener
royalti incom morphosi i-mab guid
bla submiss program current paus new patient
enrol due phase membran
nephropathi program disclos previous otilimab phase studi
ra led gsk op expect otilimab contribut royalti incom
like despit unsuccess develop indic
ms hand oa
revenu oper expens cash
balanc strong tremfya growth morphosi report
revenu major come
recognit mp up-front payment
op report tremfya sale y/i impli
royalti incom morphosi past quarter
tremfya continu grow rapidli expect expense-fre royalti
incom gener signific valu morphosi come year
benefit financi gener deal morphosi
cash hand allow larger intern capabl
rest year manag re-affirmed financi
guidanc total revenu exclud tafa sale
 expens oper incom
base guidanc compani number
anticip higher oper expens higher quarterli
basi vs remain part
revenu forecast increas includ otilimab
valuat pt reiter op base progress
sever late-stag program report morphosi partner
includ royalti incom multipl myeloma
china otilimab ra forecast probabl adjust
basi expect launch china otilimab
launch us around ad two asset
revenu forecast increas revenu
forecast also moder increas due higher
expect revenu tafasitamab forecast remain unchang
continu expect us approv year eu launch
revenu forecast higher consensu
lower oper expens estim
moder decreas due lower expect
expens increas anticip faster-
expand corpor capac combin dilut
ep forecast higher lower roughli flat
higher base chang
price target increas reiter outperform
rate morphosyss stock
price target morphosi mor us adr rate
stock outperform morphosi german biopharmaceut compani long legaci
innov therapeut monoclon antibodi discoveri develop histor
morphosi taken care path build broad portfolio skinni collabor
bigger biopharma compani result potenti low-to-mid singl digit
royalti product collabor final come fruition first
reach market tremfya begin gener royalti
morphosi believ larger basi compani valu howev morphosi anti-
tafasitamab hematolog malign global collabor
collabor program certainli bring morphosi attract guarante up-front
equiti conting mileston payment well robust royalti
ultim success tafasitamab rest parti collect commerci effort
us commerci execut outsid us tafasitamab shown impress data
single-arm phase trial patient transplant-inelig relaps refractori dlbcl
endors us fda data appear suffici acceler approv
tafasitamab abl gener revenu rang
still potenti develop larger popul sever differ
form non-hodgkin lymphoma nhl import asset mor stock
royalti jnj op antibodi psoriasi
price target mor base dcf methodolog cash flow
termin growth driver forecast royalti tremfya
risk-adjust sale tafasitamab assum discount rate base compani
wacc addit factor mor cash balanc valuat
risk view outlook valuat morphosi includ failur obtain approv
tafasitamab either us ex-u jurisdict base l-mind forecast
product also subject risk better-than-expect market share gain
competit brand product roch polatuzumab lack willing
physician patient chang new treatment tafasitamab long-standing
treatment option payer us europ could also refus reimburs expens
combin tafasitamab plu revlimid could potenti cost
year treatment addit morphosi current sole sourc incom royalti tremfya
could lower expect due chang highli competit immunolog treatment
market risk morphosi includ develop regulatori disappoint
partner out-licens antibodi two product fail compani valuat
would reduc approxim
sale
share count period basic/dilut
mor guidanc mm
pipelin program includ current model
pipelin program exclud current
trial complet
top-line result
sec gov compani websit present svb leerink analysi
brand
type event
event trial detail
date known
up/down
expect
phase start earli
svb leerink llc equiti research compani file
million
royalti mileston po adjust
svb leerink llc research compani file
million
sale
 total revenu
sg total revenu
svb leerink llc research compani file
mm
pv flow
equiti
debt
